The Constance Monitto Lab conducts clinical research on pediatric pain management as well as basic science studies on chemotherapy resistance. In our pediatric pain management research, we work to assess the impact of low-dose opioid antagonism on opioid-related side effects, such as nausea and vomiting. We also analyze data on current methods of pediatric pain management in the United States. In addition, our team uses basic science studies to assess the success of epigenetic gene regulation on the development of resistance to chemotherapeutic agents in cancer.

Dr. Petty's laboratory interests focuses on antimicrobial chemotherapy, hospital-based medical practices, and internal medicine collaboration with ophthalmologic clinical trials.

Research in the Eric Nuermberger Lab focuses primarily on experimental chemotherapy for tuberculosis. We use proven murine models of active and latent tuberculosis infection to assess the effectiveness of novel antimicrobials. A key goal is to identify new agents to combine with existing drugs to shorten tuberculosis therapy or enable less frequent drug administration. We're also using a flow-controlled in vitro pharmacodynamic system to better understand the pharmacodynamics of drug efficacy and the selection of drug-resistant mutants during exposure to current agents.

The Theresa Shapiro Laboratory studies antiparasitic chemotherapy. On a molecular basis, we are interested in understanding the mechanism of action for existing antiparasitic agents, and in identifying vulnerable metabolic targets for much-needed, new, antiparasitic chemotherapy. Clinically, our studies are directed toward an evaluation, in humans, of the efficacy, pharmacokinetics, metabolism and safety of experimental antiparasitic drugs.

The Ronen Shechter Lab is currently investigating a novel treatment for nerve pain induced by chemotherapy. Our previous research has involved studying the role and mechanism of peripheral opioids as well as the use of dorsal column stimulation to treat pain resulting from a condition affecting the nervous system.

Reid Thompson’s research interests include evaluation of ventricular function in patients with muscular dystrophy and Barth syndrome, and in patients who have completed chemotherapy. He also studies novel methods of teaching and diagnosing heart disease through cardiac auscultation.

The Stivers Lab is broadly interested in the biology of the RNA base uracil when it is present in DNA. Our work involves structural and biophysical studies of uracil recognition by DNA repair enzymes, the central role of uracil in adapative and innate immunity, and the function of uracil in antifolate and fluoropyrimidine chemotherapy. We use a wide breadth of structural, chemical, genetic and biophysical approaches that provide a fundamental understanding of molecular function. Our long-range goal is to use this understanding to design novel small molecules that alter biological pathways within a cellular environment. One approach we are developing is the high-throughput synthesis and screening of small molecule libraries directed at important targets in cancer and HIV-1 pathogenesis.

Our lab is focused on using comprehensive gene expression, methylation and sequencing and metabolomics analysis to identify alterations in breast cancer, and exploiting these for early detection and therapy. Among deferentially expressed genes, our lab has focused on the HOX genes. HOX genes are intimately involved in the development of resistance to both chemotherapy and to agents targeting the estrogen receptor. Our work explores the alternate pathways that are activated by HOX proteins leading to this resistance and novel treatments to overcome resistance in both tissue culture and xenograft models. In addition, epigenetically silenced genes and a metabolic reprogramming in tumors also trigger novel early detection and therapeutic strategies. We are testing the utility of differentiation therapy through reactivating RAR-beta in breast cancer using histone deacetylase inhibitors with great success. Also, we are targeting enzymes involved in gluconeogenesis and glycolysis with small molecule FDA-approved antimetabolites to achieve antitumor effects.